Key result
Among patients with unexplained left ventricular hypertrophy and preexcitation, Danon disease was present in 30% and associated with more neurological involvement (100% vs 0%, P=0.008).
Why the study?
Cardiac involvement in Danon disease typically manifests as left ventricular hypertrophy and ventricular preexcitation, prompting the identification of Danon disease among patients with both features.
Observational (n=10)
Absolute Event Rate: 100% vs 0%
p-value: p=0.008
In patients with unexplained LVH and ventricular preexcitation, Danon disease is highly prevalent (30%) and presents with distinct clinical and ECG features such as earlier onset and wider QRS complexes.
Supports targeted Danon testing in unexplained LVH with preexcitation; leaves open validation in larger prospective cohorts.
BACKGROUND: Cardiac involvement in Danon disease typically manifests as left ventricular hypertrophy (LVH) and ventricular preexcitation. This study aimed to identify patients with Danon disease among patients with LVH and concurrent electrocardiographic preexcitation. METHODS: Electrocardiographic preexcitation was identified in 10 of 197 patients with unexplained LVH in whom genetic testing was performed using next-generation sequencing. RESULTS: Three (3/10, 30%) patients with Danon disease were found in association with different mutations in the gene of lysosome-associated membrane protein 2 (LAMP2). Compared to seven patients without Danon disease, these three patients presented with distinctive clinical phenotypes, including onset at an earlier age (20 ± 2 years vs. 53 ± 9 years, p < 0.001), more neurological involvements (100% vs. 0, p = 0.008), higher electrocardiographic voltages (10 ± 1 mV vs. 5 ± 1 mV, p < 0.001), wider QRS complexes (163 ± 5 ms vs. 115 ± 20 ms, p = 0.006), less common asymmetric hypertrophy (0% vs. 86%, p = 0.033), and more frequent elevation of three serum enzymes (creatine kinase, aspartate aminotransferase, and lactate dehydrogenase). Intracellular vacuoles accumulation with deficiencies of LAMP2 protein was found in both cardiac and skeletal myocytes of patients with Danon disease. CONCLUSION: In patients with coexistent LVH and ventricular preexcitation, Danon disease is common with distinctive clinical presentations. Comprehensive assessment of these resemble patients can provide valuable findings for early identification and clinical decision making of patients with Danon disease.
No takes yet. Share an insight, caveat, or question.
Liu et al. (2019) conducted an observational in Left ventricular hypertrophy and concomitant electrocardiographic preexcitation (n=10). Danon disease (LAMP2 mutation) vs. Without Danon disease was evaluated on Neurological involvements (p=0.008). Among patients with unexplained left ventricular hypertrophy and preexcitation, Danon disease was present in 30% and associated with more neurological involvement (100% vs 0%, P=0.008).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: